Q4FY17 Results: Dr Reddy's Laboratories
Amir Shaikh / 12 May 2017
Dr Reddy's Laboratories reported its results for the quarter ended March 31, 2017 on Friday.
Dr Reddy's Laboratories reported its results for the quarter ended March 31, 2017 on Friday.
The company's total sales for Q4FY17 came in at Rs 3611.9 crore, which represents a 2.99 per cent sequential decline and 4.82 per cent YoY decline.
Its operating profit (EBIT) for the quarter amounted to Rs 336.2 crore and its EBIT margin stood at 9.31 per cent.
It reported PAT of Rs 327.4 crore, which represents a sequential QoQ decline of 32.27 per cent and a YoY increase of 180.55 per cent.
The board of directors has recommended a final dividend Rs 20 per equity share on the face value of Rs 5 each for FY16-17.
The stock opened at Rs 2593 and touched its 52-week low of Rs 2525.25 on the BSE.
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The company operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI), and proprietary products.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.